A tetravalent live-attenuated dengue vaccine was manufactured in India after receipt of vaccine strains from NIAID, NIH, USA.
Vaccine. (Representational image)
An expert committee under the Central Drug Regulatory Authority has recommended the continuation of a phase-II clinical trial of the Serum Institute of India (SII)’s vaccine against dengue after noting the promising results of the phase-I interim clinical trial. A tetravalent live-attenuated dengue vaccine was manufactured in India after receipt of vaccine strains from NIAID, NIH, USA.